Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Patient Officer | February 15, 2019 | March 06, 2019 |
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | June 25, 2024 | June 27, 2024 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
GILEAD SCIENCES, INC.
Report date February 15, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,046 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 330 · Balance 58,046 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.01 · Expires 2029-03-01 | Direct | 9,640 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Grant · Acquired 9,640 · Balance 9,640 F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,530 |
Reported balance
After 2019-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-01 · Grant · Acquired 1,890 · Balance 15,530 F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
Lunai Bioworks Inc.
Report date June 25, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2034-06-25 | Direct | 48,137 |
Reported balance
After 2024-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-25 · Grant · Acquired 48,137 · Balance 48,137 |
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,685 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,685 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2015 Filed Sep 17, 2015 19:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $110.00 | $550,000.00 |
DisclosureSEC source: 0001104659-15-065754 · a4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,422 Read SEC document |
| September 15, 2015 Filed Sep 17, 2015 19:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $24.30 | $121,475.00 |
DisclosureSEC source: 0001104659-15-065754 · a4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 19:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,625 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-15-013021 · edgar.xml · derivative · entry 7 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,742 Underlying: Common Stock · 8,625 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 19:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,375 | $0.00 Strike: $23.76 | $0.00 |
DisclosureSEC source: 0001179110-15-013021 · edgar.xml · derivative · entry 6 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,375 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 19:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $104.11 | $62,467.08 |
DisclosureSEC source: 0001179110-15-013021 · edgar.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,422 F6 · price: Sale prices reported for the transactions reported here range from $104.01 to $104.32. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 19:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,495 | $103.49 | $361,705.24 |
DisclosureSEC source: 0001179110-15-013021 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,022 F5 · price: Sale prices reported for the transactions reported here range from $102.99 to $103.98. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 19:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,905 | $102.32 | $808,835.65 |
DisclosureSEC source: 0001179110-15-013021 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F4 · price: Sale prices reported for the transactions reported here range from $101.91 to $102.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 19:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,375 | $23.76 | $32,663.13 |
DisclosureSEC source: 0001179110-15-013021 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 19:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,625 | $24.30 | $209,544.38 |
DisclosureSEC source: 0001179110-15-013021 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2015 Filed Aug 4, 2015 21:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.76 | $0.00 |
DisclosureSEC source: 0001179110-15-011694 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375 Underlying: Common Stock · 15,000 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 03, 2015 Filed Aug 4, 2015 21:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,794 | $119.57 | $573,227.69 |
DisclosureSEC source: 0001179110-15-011694 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,422 F4 · price: Sale prices reported for the transactions reported here range from $119.335 to $120.05. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 03, 2015 Filed Aug 4, 2015 21:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 12,206 | $118.93 | $1,451,642.49 |
DisclosureSEC source: 0001179110-15-011694 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,216 F3 · price: Sale prices reported for the transactions reported here range from $118.33 to $119.29. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 03, 2015 Filed Aug 4, 2015 21:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $23.76 | $356,325.00 |
DisclosureSEC source: 0001179110-15-011694 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.76 | $0.00 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · derivative · entry 8 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,375 Underlying: Common Stock · 15,000 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 535 | $117.95 | $63,100.90 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · nonDerivative · entry 7 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,422 F8 · price: Sale prices reported for the transactions reported here range from $117.61 to $118.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 700 | $116.90 | $81,832.03 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · nonDerivative · entry 6 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,957 F7 · price: Sale prices reported for the transactions reported here range from $116.59 to $117.19. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 765 | $115.91 | $88,674.13 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,657 F6 · price: Sale prices reported for the transactions reported here range from $115.46 to $116.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,263 | $117.92 | $384,786.99 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,422 F5 · price: Sale prices reported for the transactions reported here range from $117.60 to $118.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,907 | $117.01 | $574,149.42 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,685 F4 · price: Sale prices reported for the transactions reported here range from $116.5456 to $117.53. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,830 | $115.94 | $791,902.30 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,592 F3 · price: Sale prices reported for the transactions reported here range from $115.4991 to $116.36. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $23.76 | $356,325.00 |
DisclosureSEC source: 0001179110-15-010897 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,625 | $0.00 Strike: $23.76 | $0.00 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · derivative · entry 8 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,375 Underlying: Common Stock · 10,625 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · derivative · entry 7 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $114.36 | $114,364.40 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · nonDerivative · entry 6 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,422 F6 · price: Sale prices reported for the transactions reported here range from $114.04 to $114.6484. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $113.35 | $113,354.00 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,422 F5 · price: Sale prices reported for the transactions reported here range from $112.89 to $113.82. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,044 | $114.31 | $690,867.28 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,422 F4 · price: Sale prices reported for the transactions reported here range from $113.73 to $114.71. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,956 | $113.14 | $1,013,305.13 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,466 F3 · price: Sale prices reported for the transactions reported here range from $112.72 to $113.7022. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,625 | $23.76 | $252,396.88 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,375 | $23.60 | $103,250.00 |
DisclosureSEC source: 0001179110-15-009084 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2015 Filed May 19, 2015 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 625 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001179110-15-008136 · edgar.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,375 Underlying: Common Stock · 625 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 15, 2015 Filed May 19, 2015 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 24,375 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-15-008136 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,375 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 15, 2015 Filed May 19, 2015 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 25,000 | $110.01 | $2,750,210.00 |
DisclosureSEC source: 0001179110-15-008136 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,422 F4 · price: Sale prices reported for the transactions reported here range from $110.00 to $110.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 15, 2015 Filed May 19, 2015 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 625 | $23.60 | $14,750.00 |
DisclosureSEC source: 0001179110-15-008136 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2015 Filed May 19, 2015 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 24,375 | $19.09 | $465,196.88 |
DisclosureSEC source: 0001179110-15-008136 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2015 Filed May 5, 2015 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-15-007167 · edgar.xml · derivative · entry 6 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 Underlying: Common Stock · 10,000 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 01, 2015 Filed May 5, 2015 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,380 | $106.05 | $146,345.14 |
DisclosureSEC source: 0001179110-15-007167 · edgar.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,422 F6 · price: Sale prices reported for the transactions reported here range from $105.95 to $106.29. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2015 Filed May 5, 2015 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,677 | $105.47 | $176,865.48 |
DisclosureSEC source: 0001179110-15-007167 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,802 F5 · price: Sale prices reported for the transactions reported here range from $104.94 to $105.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2015 Filed May 5, 2015 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,240 | $104.34 | $233,714.88 |
DisclosureSEC source: 0001179110-15-007167 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,479 F4 · price: Sale prices reported for the transactions reported here range from $103.93 to $104.922. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2015 Filed May 5, 2015 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,703 | $103.23 | $691,945.33 |
DisclosureSEC source: 0001179110-15-007167 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,719 F3 · price: Sale prices reported for the transactions reported here range from $102.89 to $103.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2015 Filed May 5, 2015 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $19.09 | $190,850.00 |
DisclosureSEC source: 0001179110-15-007167 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2015 Filed Apr 9, 2015 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-15-006184 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,375 Underlying: Common Stock · 5,000 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| April 08, 2015 Filed Apr 9, 2015 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $100.00 | $500,000.00 |
DisclosureSEC source: 0001179110-15-006184 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,422 Read SEC document |
| April 08, 2015 Filed Apr 9, 2015 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $19.09 | $95,425.00 |
DisclosureSEC source: 0001179110-15-006184 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-15-005996 · edgar.xml · derivative · entry 6 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 5,000 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 675 | $97.13 | $65,564.78 |
DisclosureSEC source: 0001179110-15-005996 · edgar.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,422 F6 · price: Sale prices reported for the transactions reported here range from $96.78 to $97.60. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,325 | $96.29 | $127,581.87 |
DisclosureSEC source: 0001179110-15-005996 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,097 F5 · price: Sale prices reported for the transactions reported here range from $95.73 to $96.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,400 | $97.06 | $135,886.10 |
DisclosureSEC source: 0001179110-15-005996 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,422 F4 · price: Sale prices reported for the transactions reported here range from $96.8008 to $97.71. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,600 | $96.30 | $346,682.52 |
DisclosureSEC source: 0001179110-15-005996 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,822 F3 · price: Sale prices reported for the transactions reported here range from $95.7981 to $96.77. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $19.09 | $95,425.00 |
DisclosureSEC source: 0001179110-15-005996 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2015 Filed Mar 5, 2015 00:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-15-004233 · edgar.xml · derivative · entry 6 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,375 Underlying: Common Stock · 10,000 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.